Oct 2026· Asian Journal of Pharmaceutical Research· 0 citations· 44 references
TL;DR
Artificial intelligence needs to be used to support instead of supplanting human expertise, supporting informed, patient-centered decision making and generating innovative, ethical healthcare solutions.
Abstract
Artificial intelligence (AI) has rapidly become a paradigm shift in driving in-silico research to provide new solutions to old drug discovery and development challenges. AI facilitates fast design of drugs, precise prediction of drug-target interactions, better Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling and more toxicological screenings by using machine learning, deep learning and generative algorithms. The combination of AI and molecular modeling, simulations, and multi-omics platforms will guarantee accuracy and customization in the development of therapies never previously achieved. Also, AI helps in automation, feature extraction, and natural language processing and may increase the reproducibility and broaden the nature of biomedical research. Although these improvements have been made, several challenges are still present, especially the quality of data, interpretability, ethical concerns, validation systems, and generalizability in non-homogenous populations and in rare diseases. These issues are central to the realization of the potential of AI in precision medicine. Explainable AI, federated learning, quantum computing and regulatory alignment will be the future of AI in healthcare. Finally, AI needs to be used to support instead of supplanting human expertise, supporting informed, patient-centered decision making and generating innovative, ethical healthcare solutions.
Artificial Intelligence (AI) is an important technology in drug discovery and clinical trials, particularly for handling and analysis of large and complex chemical, biological, and clinical datasets. Machine learning, deep learning, natural language processing, reinforcement learning, and generative AI are being applie...
Talari Chowdeswari, G. Madhuri, J. Poojitha et al.· International Journal of Pha...· 0 citations
Artificial intelligence (AI) is changing the way we discover anticancer drugs. It tackles the problems of traditional methods, such as prolonged timelines for drug development, higher costs, and substantial inter-patient heterogeneity. This review explains how AI is applied throughout the cancer drug pipeline. This inc...
Faizan Ul Haque Nagrami, Pahchan Shukla, Ruchi Yadav et al.· Frontiers in Oncology· 1 citation
Recent applications of AI, machine learning (ML), deep learning (ML), deep learning (DL), deep reinforcement learning (RL), reinforcement learning (RL), natural language processing (NLP), and generative AI across major stages of the drug discovery pipeline are examined.
Uma Rawat, Anita Singh· Current Computer - Aided Dru...· 0 citations
Drug discovery is a multifaceted and resource-intensive process traditionally marked by long development timelines, high financial costs, and significant attrition rates. The integration of Artificial Intelligence (AI) has introduced transformative opportunities to overcome these barriers by enhancing data-driven decis...
Pritam Juvatkar, Chaitrali Bidikar, Aditi Arun Mhatre· Role of AI in Drug discovery...· 0 citations
This review discusses how AI can accelerate computational drug discovery, virtual screening (VS), and the repurposing of already-approved medications, and it can also optimize combination therapies through computational simulation.
D. Bhagwat, Sonali A. Chikhalwale, S. Mali et al.· Current pharmaceutical desig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.